Tildrakizumab Prefilled Syringe for Psoriasis

Study Summary

This trial will study how well an experimental drug works in people with psoriasis. The purpose of this trial is to test the safety and effectiveness of Tildrakizumab Prefilled Syringe in the treatment of Psoriasis. This is a Phase 3 clinical trial, which means that it is the last stage of testing before the drug is submitted for FDA approval. Because this trial is double-blinded, neither the patients nor the doctors will know who is receiving the active drug and who is receiving the placebo. The trial will involve 300 patients with moderate to severe Psoriasis. It will last for 16 weeks.The trial is being conducted by Sun Pharma, the manufacturer of Tildrak

Treatment Effectiveness

Trial Safety

Trial Design

Trial Logistics

Closest Location: University of California, San Francisco · San Francisco, CA

2008First Recorded Clinical Trial

6 TrialsResearching Psoriasis

691 CompletedClinical Trials

Eligibility Criteria

About The Reviewer

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.